The decision to do business with Pharmascience is a good one based on several factors which, taken together, represent a clear advantage over others in our field.
As an innovative, global developer and manufacturer of a wide range of high quality generic drugs, with an excellent reputation and a solid market position in Canada, we are fast-to-market ? something that all of our global partners greatly appreciate.
Although already firmly established internationally, we seek to grow our business even further. Our competitive advantage comes down to optimum flexibility in our approach to global partnerships. Everything we do in the international arena is custom-tailored to the market conditions and the particulars of the contract we forge with our partners.
Couple this with world-class R&D, a global operations team comprised of dedicated professionals with in-depth experience in their field, and first-class, country-specific marketing and promotional expertise, and you have a formula for success that represents the gold standard in the generic-drug industry.
Significant Pipeline with fully integrated R&D Platform
Working in one of the finest Research and Development facilities in Canada, our R&D Team is among the company's strongest assets and pursues well over 100 projects at any given time.
Our R&D activities are intended to develop generic drugs that meet Canadian and International standards/criteria for bioequivalence and bioavailability and to identify new therapeutic uses and delivery systems for drugs already developed to treat specific illnesses.
Over the last 10 years, Pharmascience has initiated major expansion projects estimated at over CAD$150 million in order to meet growing global demand. The recent acquisition of Aegera Therapeutics Inc., a Montreal-based clinical-stage biotechnology company focused on developing targeted therapeutics to address unmet major medical needs, primarily in oncology will further add to our development capabilities.
State-of-the-Art Global Operations
Our Global Operations Team ensures that top-quality products reach consumers worldwide at the lowest possible cost.
Dealing with close to 250 families of pharmaceutical products spread over 1100 finished goods, the 600 members of our global operations team manage more than 6,500 stock-keeping units, including finished goods, bulk, active pharmaceutical ingredients, excipient and packaging components, spending over CAD $100 million a year in procurement for these different units.
Using a hybrid manufacturing strategy, with some products produced in-house and others manufactured through supply agreements with select suppliers, we are experienced at meeting the specific labelling, language, packaging format, and volume demands of our global clientele.
Flexibility and turnaround times are outstanding, thanks in part to the sophisticated management systems (SAP and ERP) that the organization employs. To further enhance response time, the Global Operations Team implemented a continuous improvement culture in early 2008, using "Lean Six Sigma" tools to attain its objectives.
Substantial Regulatory Expertise
Pharmascience markets a wide range of high quality, Canadian-made bioequivalent products in over 60 countries. What?s more, we are committed to increasing our global footprint and have developed considerable expertise in international regulatory affairs and logistics for countries in the European Union and the Middle East, as well as for many other highly regulated countries in Asia, Oceania and Africa.
The mission of our international regulatory affairs team is to provide the support needed by our customers and partners to attain marketing authorizations by the local authorities, ensuring the most efficient and effective entry of Pharmascience products into global markets.
Our expert team of professionals is dedicated to the proper maintenance of foreign licenses while ensuring regulatory compliance throughout the commercial life-cycle of internationally marketed products. We are also proud to note that Pharmascience is able to deliver ten or more new generic drugs per year for international markets.